These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 24766186)

  • 1. Anti-neuropilin 1 antibody Fab' fragment conjugated liposomal docetaxel for active targeting of tumours.
    Manjappa AS; Goel PN; Gude RP; Ramachandra Murthy RS
    J Drug Target; 2014 Sep; 22(8):698-711. PubMed ID: 24766186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
    Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
    Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
    Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
    Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.
    Pastorino F; Brignole C; Marimpietri D; Sapra P; Moase EH; Allen TM; Ponzoni M
    Cancer Res; 2003 Jan; 63(1):86-92. PubMed ID: 12517782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is an alternative drug delivery system needed for docetaxel? The role of controlling epimerization in formulations and beyond.
    Manjappa AS; Goel PN; Vekataraju MP; Rajesh KS; Makwana K; Ukawala M; Nikam Y; Gude RP; Murthy RS
    Pharm Res; 2013 Oct; 30(10):2675-93. PubMed ID: 23756759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphoid tissue targeting of anti-HIV drugs using liposomes.
    Désormeaux A; Bergeron MG
    Methods Enzymol; 2005; 391():330-51. PubMed ID: 15721390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
    Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB
    Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular association and cytotoxicity of doxorubicin-loaded immunoliposomes targeted via Fab' fragments of an anti-CD74 antibody.
    Lundberg BB; Griffiths G; Hansen HJ
    Drug Deliv; 2007 Mar; 14(3):171-5. PubMed ID: 17454037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments.
    Sapra P; Moase EH; Ma J; Allen TM
    Clin Cancer Res; 2004 Feb; 10(3):1100-11. PubMed ID: 14871990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated polyethylenimine-Fab' antibody fragment conjugates for targeted gene delivery to human ovarian carcinoma cells.
    Merdan T; Callahan J; Petersen H; Kunath K; Bakowsky U; Kopecková P; Kissel T; Kopecek J
    Bioconjug Chem; 2003; 14(5):989-96. PubMed ID: 13129403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
    Cheng WW; Allen TM
    J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
    Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and in vitro evaluation of anti-VCAM-1-Fab'-conjugated liposomes for the targeted delivery of the poorly water-soluble drug celecoxib.
    Kang DI; Lee S; Lee JT; Sung BJ; Yoon JY; Kim JK; Chung J; Lim SJ
    J Microencapsul; 2011; 28(3):220-7. PubMed ID: 21425947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma.
    Brignole C; Marimpietri D; Gambini C; Allen TM; Ponzoni M; Pastorino F
    Cancer Lett; 2003 Jul; 197(1-2):199-204. PubMed ID: 12880982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes.
    Gao J; Zhong W; He J; Li H; Zhang H; Zhou G; Li B; Lu Y; Zou H; Kou G; Zhang D; Wang H; Guo Y; Zhong Y
    Int J Pharm; 2009 Jun; 374(1-2):145-52. PubMed ID: 19446771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo.
    Maruyama K; Takahashi N; Tagawa T; Nagaike K; Iwatsuru M
    FEBS Lett; 1997 Aug; 413(1):177-80. PubMed ID: 9287139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo.
    Shi C; Cao H; He W; Gao F; Liu Y; Yin L
    Biomed Pharmacother; 2015 Jul; 73():48-57. PubMed ID: 26211582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction and evaluation of pH-sensitive immunoliposomes for enhanced delivery of anticancer drug to ErbB2 over-expressing breast cancer cells.
    Li T; Amari T; Semba K; Yamamoto T; Takeoka S
    Nanomedicine; 2017 Apr; 13(3):1219-1227. PubMed ID: 27965166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel strategy affords high-yield coupling of antibody Fab' fragments to liposomes.
    Shahinian S; Silvius JR
    Biochim Biophys Acta; 1995 Nov; 1239(2):157-67. PubMed ID: 7488620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
    Mamot C; Drummond DC; Noble CO; Kallab V; Guo Z; Hong K; Kirpotin DB; Park JW
    Cancer Res; 2005 Dec; 65(24):11631-8. PubMed ID: 16357174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.